Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders
- PMID: 1671782
- DOI: 10.1038/jcbfm.1991.53
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders
Abstract
The purpose of the present study is to visualize and quantify dopamine D2 receptors in the living human brain using an 123I-labeled ligand and the single photon emission computerized tomography (SPECT) technique. S-(-)-Iodobenzamide [S-(-)-IBZM] has been shown to be a highly selective ligand with high affinity for D2 receptors in experimental studies. Five millicuries (185 MBq) of 123I-labeled S-(-)-IBZM was administered intravenously to 12 control subjects, 22 parkinsonian patients under L-Dopa therapy, 12 parkinsonian patients without L-Dopa, 10 unmedicated patients with Huntington's disease, and 12 patients under different neuroleptics. Data collection with a rotating double-head scintillation camera started 1 h after injection and lasted for 50 min. In a semiquantitative approach, a ratio was calculated between mean counts per pixel in the striatum and a region in the lateral frontal cortex, which was 1.74 +/- 0.10 in the control group. A marked reduction of this ratio was found in patients with Huntington's disease (1.38 +/- 0.12; p = 0.0001), no significant changes in untreated parkinsonian patients (1.67 +/- 0.14), but a reduction in L-Dopa-treated cases (1.59 +/- 0.13; p = 0.0014). A curvilinear relationship was found between total daily dose of neuroleptics and the reduction of this ratio. Estimated receptor blockade under full neuroleptic treatment was 75-80%. S-(-)-IBZM binding was reduced with increasing age (p less than 0.01). Specific binding was reduced markedly when the racemic mixture of IBZM was used, and no specific binding was seen with the R-(+)-isomer, demonstrating the stereoselectivity of IBZM binding.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Dopamine D2 receptor imaging and measurement with SPECT.Adv Neurol. 1993;60:494-500. Adv Neurol. 1993. PMID: 8420177
-
Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.J Nucl Med. 1997 Nov;38(11):1711-7. J Nucl Med. 1997. PMID: 9374338
-
[Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].Radiologe. 1995 Nov;35(11):838-43. Radiologe. 1995. PMID: 8657887 German.
-
Dopamine receptors in Parkinson's disease.Neurol Clin. 1992 May;10(2):377-86. Neurol Clin. 1992. PMID: 1584180 Review.
-
Dopamine receptor classification, neuroanatomical distribution and in vivo imaging.Wien Klin Wochenschr. 1991;103(21):639-46. Wien Klin Wochenschr. 1991. PMID: 1771898 Review.
Cited by
-
Glutamate and dopamine in schizophrenia: an update for the 21st century.J Psychopharmacol. 2015 Feb;29(2):97-115. doi: 10.1177/0269881114563634. Epub 2015 Jan 13. J Psychopharmacol. 2015. PMID: 25586400 Free PMC article. Review.
-
BDNF and Huntingtin protein modifications by manganese: implications for striatal medium spiny neuron pathology in manganese neurotoxicity.J Neurochem. 2014 Dec;131(5):655-66. doi: 10.1111/jnc.12926. Epub 2014 Sep 2. J Neurochem. 2014. PMID: 25099302 Free PMC article.
-
Prefronto-striatal physiology is associated with schizotypy and is modulated by a functional variant of DRD2.Front Behav Neurosci. 2014 Jul 9;8:235. doi: 10.3389/fnbeh.2014.00235. eCollection 2014. Front Behav Neurosci. 2014. PMID: 25071490 Free PMC article.
-
Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.Mol Pharm. 2013 Mar 4;10(3):793-812. doi: 10.1021/mp3005325. Epub 2013 Jan 24. Mol Pharm. 2013. PMID: 23294202 Free PMC article. Review.
-
SPECT imaging evaluation in movement disorders: far beyond visual assessment.Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):764-73. doi: 10.1007/s00259-010-1664-1. Epub 2010 Dec 2. Eur J Nucl Med Mol Imaging. 2011. PMID: 21125269 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical